Hyperfine (HYPR) said Tuesday it has agreed to sell about 4.5 million shares along with warrants to purchase up to approximately 4.5 million shares at a price of $1.33 per share-and-warrant pair in a registered direct offering.
The health technology company said gross proceeds are expected to total $6.0 million once the offering closes Wednesday.
Hyperfine said it plans to use net proceeds for working capital and general corporate purposes.
Shares of the company were down more than 14% in Tuesday's premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。